Schedule
Update on Severe Asthma 2021
DATE: THURSDAY AND Friday, March 25-26, 2021
LOCATION: Live On-Line (with recorded presentations available for 1 month following the course)For additional information, call Chris Fanta at 617-732-4353
MARCH 25, 2021 – Day 1: Understanding Asthma
| 9:25-9:30 a.m. EDT | Welcome and introduction | E. Israel, C. Fanta |
| 9:30 – 10:05 | Genetic Diseases and Airway Obstruction | B. Raby |
| 10:05 – 10:40 | Severe Asthma in the Age of Corona Virus and Racial Injustice | M. Louisias |
| 10:40—11:15 | Occupational Exposures and Severe Asthma | R. McCunney |
| 11:15 – 12:00 | Workshop A: Microbiome and the Development of Asthma Workshop B: Vitamin D, Lung Development, & the Origins of Asthma Workshop C: Lipoxins and Severe Asthma |
K. Lee‐Sarwar S. Weiss B. Levy |
| 12:00 – 12:30 | Guest Lecture: New Findings in European Severe Asthma Cohorts | S.-E Dahlén |
| Break | ||
| 2:30-3:05 | Obesity and Asthma | A. Dixon |
| 3:05 – 3:40 | Asthma in Schools | W. Phipatanakul |
| Special Consideration | ||
| 3:40-4:15 | ABPA and Eosinophilic Lung Disease | J. Boyce |
| 4:15-5:00 | Case Discussions: Diagnostic Dilemmas | Panel |
MARCH 26, 2021 – DAY 2: TREATING ASTHMA
| 9:30-10:05 a.m. EDT | Evaluation of Severe Asthma: A Systematic Approach | N. Barrett |
| 10:05 – 10:40 | Insights from the GINA and NAEPP Asthma Guidelines | C. Fanta |
| 10:40 – 11:15 | Choosing Among the Biologics for Severe Asthma | E. Israel |
| 11:15—11:50 | Stepping‐Up Care in Children with Severe Asthma | K. Haver |
| 11:50 – 12:30 | Workshop D: Gastroesophageal Reflux and Severe Asthma Workshop E: Laryngeal Disordered Breathing Mimicking Severe Asthma Workshop F: Treating Rhinosinusitis and Nasal Polyposis |
W. Chan A. Maxfield |
| Break | ||
| 2:30-3:05 | Aspirin‐Exacerbated Respiratory Disease | T. Laidlaw |
| 3:05 – 3:50 | Bronchial Thermoplasty: Pro and Con | S.Majid and E. Israel |
| 3:50-4:25 | Novel Therapies: A Look into the Future | E. Israel |
| 4:25-5:00 | Case Discussions: Therapeutic Dilemmas | Panel |
Accreditation:
ACCREDITATION COUNCIL FOR CONTINUING MEDICAL EDUCATION
The Harvard Medical School is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.
The Harvard Medical School designates this live activity for a maximum of 11.00 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
NURSE PRACTITIONERS and REGISTERED NURSES
For the purpose of recertification, the American Academy of Nurse Practitioners Certification Board and American Nurses Credentialing Center accept AMA PRA Category 1 Credit™ issued by organizations accredited by the ACCME (Accreditation Council for Continuing Medical Education). We would also suggest that learners check with their state licensing board to ensure they accept reciprocity with AMA PRA Category 1 Credit™ for re-licensure.
PHYSICIAN ASSISTANTS
The National Commission on Certification of Physician Assistants (NCCPA) states that AMA PRA Category 1 Credits™ are acceptable for continuing medical education requirements for recertification. We would also suggest that learners check with their state licensing board to ensure they accept reciprocity with AMA PRA Category 1 Credit™ for re-licensure.
CANADIAN ACCREDITATION
The Royal College of Physicians and Surgeons of Canada recognizes conferences and workshops held outside of Canada that are developed by a university, academy, hospital, specialty society or college as accredited group learning activities.
DISCLOSURE POLICY
Harvard Medical School (HMS) adheres to all ACCME Accreditation Criteria and Policies. It is HMS’s policy that those who have influenced the content of a CME activity (e.g. planners, faculty, authors, reviewers and others) disclose all relevant financial relationships with commercial entities so that HMS may identify and resolve any conflicts of interest prior to the activity. These disclosures will be provided in the activity materials along with disclosure of any commercial support received for the activity. Additionally, faculty members have been instructed to disclose any limitations of data and unlabeled or investigational uses of products during their presentations.
